Our results show a 20-fold increase in INS-IGF2 expression levels in tumor tissues of relapse patients than that of complete remission patients (p value < 0.001), whereas IGF2 expression differs by less than twofold between these groups (Fig. 5b). The gene discussed is IGF2; the disease is neoplasm.